<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Lenalidomide is an oral immunomodulatory drug derived from thalidomide </plain></SENT>
<SENT sid="1" pm="."><plain>This drug has been approved by the Food and Drug Administration for transfusion-dependent <z:hpo ids='HP_0001903'>anemia</z:hpo> due to low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) associated with deletion 5q abnormality with or without additional cytogenetic abnormalities and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> in combination with <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Trials have been conducted for its use in higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>AREAS COVERED: The pharmacokinetic and mechanism of action are discussed and clinical studies of lenalidomide in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> are reported herein in detail </plain></SENT>
<SENT sid="4" pm="."><plain>An overview of safety and tolerability is also presented </plain></SENT>
<SENT sid="5" pm="."><plain>EXPERT OPINION: Lenalidomide has clinical activity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with manageable toxicity </plain></SENT>
<SENT sid="6" pm="."><plain>The population that would benefit from lenalidomide and optimal dose needs to be better defined </plain></SENT>
<SENT sid="7" pm="."><plain>Recent trials have focused on combining lenalidomide with other agents active in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and promising data are emerging </plain></SENT>
</text></document>